Pharsight

Drug name - Austedo

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8524733 TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Apr, 2031

(8 years from now)

US9550780 TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(10 years from now)

CN104311552A TEVA BRANDED PHARM Vesicular Monoamine Transporter 2 Benzoquinoline Inhibitor
Nov, 2016

(5 years ago)

CN104684555A TEVA BRANDED PHARM Preparation Medicine Dynamics Vesicle Single Ammine Transport Body Deuterated Benzene And 2 Quinoline And Its Inhibitor
Oct, 2020

(2 years ago)

CN102186848A TEVA BRANDED PHARM Benzoquinoline Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

CN102186848B TEVA BRANDED PHARM Benzene Quinoline And Inhibitor Of Vesicle Monoamine Transporter Body 2
Sep, 2029

(6 years from now)

IN296447B TEVA BRANDED PHARM Benzoquinoline Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

EP2326643B1 TEVA BRANDED PHARM Benzoquinoline Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

EP3061760B1 TEVA BRANDED PHARM Deuterated Benzoquinolizine Derivatives As Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

EP2610254A1 TEVA BRANDED PHARM Deuterated Benzoquinoline Derivatives As Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

EP2326643A2 TEVA BRANDED PHARM Benzoquinoline Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

EP3345905B1 TEVA BRANDED PHARM Deuterated Benzoquinolizine Derivatives As Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

EP2610254B1 TEVA BRANDED PHARM Deuterated Benzoquinoline Derivatives As Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

EP3061760A1 TEVA BRANDED PHARM Deuterated Benzoquinolizine Derivatives As Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

EP3345905A1 TEVA BRANDED PHARM Deuterated Benzoquinolizine Derivatives As Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

EP2326643A4 TEVA BRANDED PHARM Benzoquinoline Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524733

(Pediatric)

 TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2 Oct, 2031

(9 years from now)

US9233959 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Sep, 2033

(10 years from now)

US9814708 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Sep, 2033

(10 years from now)

US9296739 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Sep, 2033

(10 years from now)

US9233959

(Pediatric)

 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Mar, 2034

(11 years from now)

US9296739

(Pediatric)

 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Mar, 2034

(11 years from now)

US9550780

(Pediatric)

 TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Mar, 2034

(11 years from now)

US9814708

(Pediatric)

 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Mar, 2034

(11 years from now)

US10959996 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders Mar, 2036

(13 years from now)

US10959996

(Pediatric)

 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders Sep, 2036

(13 years from now)

US11179386 TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use Mar, 2038

(15 years from now)

US11179386

(Pediatric)

 TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use Sep, 2038

(15 years from now)

Drugs and Companies using DEUTETRABENAZINE ingredient

Treatment: A method of treating huntington's chorea; Treatment of tardive dyskinesia; a method of treating huntington's chorea

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
6MG TABLET;ORAL Prescription
9MG TABLET;ORAL Prescription
12MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.